AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2025
Aug 11, 2025
30751_dirs_2025-08-11_79054f74-6a7a-4bce-b5f9-a52865c493dd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-08-07
Reporting Person: O'Keefe Kenneth W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-08-07 | Ordinary Shares | A | 3507 | $0.0 | Acquired | 30477 | Direct |
| 2025-08-08 | Ordinary Shares | F | 1805 | $111.2502 | Disposed | 28672 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 4445 | Indirect |
Footnotes
F1: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.
F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F3: Shares are held for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary.